Board of Directors

S. David Kimball, Ph.D.

Dr. David Kimball joins TAXIS with more than 30 years of experience in the discovery and development of small molecule drug candidates. He currently serves as Associate Vice President for the Office of Research Commercialization (ORC) at Rutgers University. Dr. Kimball is also a Research Professor at the Ernest Mario School of Pharmacy.

Previously, Dr. Kimball was Chief Scientific Officer at Hydra Biosciences, a biopharmaceutical company focused on applying its understanding of Transient Receptor Potential (TRP) ion channels to the discovery of drugs for pain, inflammation and respiratory disease. He also served as Senior Vice President of Nonclinical Research at Pharmacopeia, Inc.

Dr. Kimball served as Vice President of Chemistry at Lexicon Pharmaceuticals, where he was responsible for building an organization of over 75 chemists, including medicinal, analytical, computational, process research and development, library synthesis and outsourcing chemistry. He spent the first 19 years of his career at Bristol-Myers Squibb Pharmaceutical Research Institute, most recently as Research Fellow in the Division of Medicinal Chemistry, Princeton, NJ.

Dr. Kimball earned his Ph.D. in Organic Chemistry/Chemical Biology from the State University of New York at Stony Brook.

Edmond J. LaVoie, Ph.D.

Founder

Dr. LaVoie is Professor and Chair of Medicinal Chemistry at the Ernest Mario School of Pharmacy at Rutgers University. He founded TAXIS in 2009, following more than 30 years of experience, during which he invented 30 issued, 27 filed and eight provisional U.S. patents and authored 220 peer-reviewed scientific publications. Prior to TAXIS, Dr. LaVoie co-founded Prodaptics Pharmaceuticals, Inc., where he addressed an early stage antiviral drug discovery concern targeting influenza viral polymerase. His many accomplishments as a synthetic organic chemist have attained him international recognition as a leader in the advancement of drug design and discovery. Dr. LaVoie has earned both an NIH MERIT Award and a Johnson and Johnson Discovery Fellowship Award. Additionally, he held the role of Associate Editor of Letters in Drug Design and Discovery and has been a member of several scientific review panels, including the NIH, NIEHS, DOE, EPA, American Cancer Society, and the American Institute for Cancer Research.

Dr. LaVoie received a B.S. in Chemistry from Fordham University. He earned a Ph.D. in Medicinal Chemistry at SUNY Buffalo.

Gregory G. Mario, M.B.A.

President and CEO

Mr. Mario joins TAXIS with more than 15 years of experience in the life sciences industry as a sales, marketing, business development, and licensing and acquisition professional. Prior to his role at TAXIS, he served as the Senior VP of Business Development with Talk America, a local-long distance telecommunications provider, and was Partner at MFP, LP, a private equity investment entity focused on the life sciences sector. Mr. Mario founded and co-founded the Brownstone Advisory Group, a real estate investment fund, and Prodaptics Pharmaceuticals, Inc., an early stage antiviral drug discovery concern targeting influenza viral polymerase.

Mr. Mario received a B.S. in Biochemistry from Trinity College. He earned an M.B.A. in Finance and Marketing at the Fuqua School of Business, Duke University.

Ernest Mario, Ph.D.

Dr. Mario currently serves as Chairman of Capnia and Chimerix, and is a Venture Partner with Pappas Ventures, a life science venture capital firm. In addition to his current and past service on several corporate boards, Dr. Mario is active in numerous educational and healthcare organizations. He is Chairman of the American Foundation for Pharmaceutical Education, a Director of the Gladstone Foundation, and past Chairman of the Duke University Health System. Dr. Mario served in management at a number of drug companies before being named in 1989 Chief Executive of Glaxo. During his tenure, Glaxo brought five major new products to market and saw sales and profits increase by 15% annually. Later Dr. Mario led drug delivery technology company Alza until selling it to Johnson & Johnson in 2001. He subsequently served as Chairman and CEO of Reliant Pharmaceuticals. Dr. Mario holds honorary doctorates from the University of Rhode Island and Rutgers University, the latter of which in 2001 renamed its pharmacy school the Ernest Mario School of Pharmacy. In 2007 he was awarded the Remington Medal by the American Pharmacists’ Association, pharmacy’s highest honor.

He received his B.S. in pharmacy from Rutgers University, and M.S. and Ph.D. in physical sciences from the University of Rhode Island.

Gail McIntyre, Ph.D.

Dr. McIntyre has more than 23 years of experience in the drug discovery and development industry at both biotechnology and pharmaceutical companies. She authored more than 30 regulatory submissions and is a board certified toxicologist with extensive experience in moving compounds through lead optimization and clinical development onto the market. Dr. McIntyre is also board certified in Clinical Pathology (hematology and clinical chemistry) by the American Society of Clinical Pathology. She served as head of Pharmaceutical Product Development LLC’s compound partnering business for 12 years before securing the position of Senior Vice President of Research at Furiex Pharmaceuticals, Inc., where she served from April 1, 2010 until December 2015.

Dr. McIntyre received her B.A. in Biology from Merrimack College. She earned M.S. and Ph.D. degrees in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.